Immunotherapy for the treatment of prostate cancer
/in Dendritic Cells, International Publications, Prostate CancerCancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma
/in Dendritic Cells, International PublicationsRandomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer
/in Dendritic Cells, International Publications, Prostate CancerDendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study
/in Dendritic Cells, International Publications, Pancreatic CancerImmune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy
/in Dendritic Cells, Glioblastoma, International PublicationsThe role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells
/in Dendritic Cells, International PublicationsDendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis
/in Dendritic Cells, Hypernephroma, International Publications, Prostate CancerOptimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF
/in Dendritic Cells, International PublicationsDendritic cells and cutaneous T-cell lymphomas
/in Dendritic Cells, International Publications, Malignant Lymphoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer